C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on February 2, 2023, covering events reported on January 30, 2023. The company is a biopharmaceutical entity incorporated in Delaware with its principal executive offices in Watertown, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of Chief Medical Officer: Adam S. Crystal, M.D., Ph.D., resigned as Chief Medical Officer, effective February 24, 2023, to pursue a head of research and development role elsewhere.
- Interim Appointment: Hagop Youssoufian, M.D., was engaged as a clinical development consultant and will serve as interim Chief Medical Officer upon Dr. Crystal's departure.
- Transition Plan: Dr. Crystal agreed to provide transitional consulting services on an as-needed basis until September 1, 2023.
Outlook, Risks, and Management Commentary
Management is conducting an ongoing search for a permanent Chief Medical Officer. Dr. Youssoufian will support operations during this interim period. The filing does not disclose specific financial risks, contingencies, or unusual items related to the company's financial performance.
Investor Verification Checklist
- Confirm the effective date of Dr. Crystal's resignation (February 24, 2023).
- Monitor the timeline for the appointment of a permanent Chief Medical Officer.
- Review the terms of the consulting agreement for Dr. Crystal's transitional services.
- Verify the scope of Dr. Youssoufian's interim responsibilities.